Abstract:Alzheimer's disease (AD) is the most common form of dementia in the elderly. However, only a few symptomatic treatments are approved for AD therapy, while no disease-modifying therapies are currently available. The amyloid cascade hypothesis posits that the deposition of amyloid β (Aβ) in the brain is the central pathological hallmark of AD. Thus, over the past 15 years, various disease-modifying immunotherapies focusing on reducing Aβ deposition have progressed from preclinical studies in AD mouse models to clinical trials in humans. Unfortunately, until now, none of the Aβ immunotherapies has produced clinically meaningful results. The main reason for this lack of efficacy is that the vaccine induces insufficiently high antibody titers, as it contains small B-cell epitope of Aβ to avoid Aβ42-specific T-cell activation. With the aim of generating a potent AD vaccine that elicits sufficiently high immunogenicity and efficiently improves cognitive capacity, we designed the protein PP-3copy-Aβ1-6-loop123, comprising three copies of Aβ1-6 inserted into three loops of a novel vaccine platform, the norovirus P particle, which could present Aβ at its surface and remarkably enhance the immunogenicity of the vaccine. We investigated the immunogenicity of PP-3copy-Aβ1-6-loop123 in three APP/PS1 transgenic mice cohorts of different ages and further determined if the vaccination using PP-3copy-Aβ1-6-loop123 had beneficial functional consequences in AD mice. Afterwards, we examined the reduction in amyloid deposition following PP-3copy-Aβ1-6-loop123 immunization in all three age cohorts and finally studied the mechanism of this novel Aβ immunotherapy. We demonstrated that PP-3copy-Aβ1-6-loop123 was able to elicit high antibody titers against Aβ42, without causing T-cell activation, in AD mice regardless of their age. Most importantly, PP-3copy-Aβ1-6-loop123 treatment successfully reduced amyloid deposition, rescued memory loss, and repaired hippocampus damage in AD mice. The Aβ antibodies induced by this active immunotherapy reacted with and disrupted aggregated Aβ, reducing its cellular toxicity. In addition, our results indicated that PP-3copy-Aβ1-6-loop123 immunization could restore Aβ homeostasis in the brain via both the “direct-targeting” and “peripheral sink” pathways. Thus, the P particle-based Aβ epitope vaccine, PP-3copy-Aβ1-6-loop123, is a sufficiently immunogenic and safe immunotherapeutic intervention for Alzheimer's disease.

Norovirus P Particle-Based Tau Vaccine-Generated Phosphorylated Tau Antibodies Markedly Ameliorate Tau Pathology and Improve Behavioral Deficits in Mouse Model of Alzheimer’s Disease

Norovirus P Particle-Based Active Aβ Immunotherapy Elicits Sufficient Immunogenicity and Improves Cognitive Capacity in a Mouse Model of Alzheimer’s Disease

Active Immunization with Norovirus P Particle-Based Amyloid-Β Chimeric Protein Vaccine Induces High Titers of Anti-Aβ Antibodies in Mice

A pentavalent peptide vaccine elicits Aβ and tau antibodies with prophylactic activity in an Alzheimer's disease mouse model

A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer's Disease.

PRECLINICAL STUDIES OF NOROVIRUS P PARTICLE-BASED ACTIVE Aβ IMMUNOTHERAPIES FOR ALZHEIMER’S DISEASE

Development of an anti-tauopathy mucosal vaccine specifically targeting pathologic conformers

Self-assembly Hollow Manganese Prussian White Nanocapsules Attenuate Tau-related Neuropathology and Cognitive Decline.

A New Chiral Pyrrolyl Alpha-Nitronyl Nitroxide Radical Attenuates Beta-Amyloid Deposition And Rescues Memory Deficits In A Mouse Model Of Alzheimer Disease

Norovirus P particle: An excellent vaccine platform for antibody production against Alzheimer’s disease

A New Chiral Pyrrolyl α-Nitronyl Nitroxide Radical Attenuates β-Amyloid Deposition and Rescues Memory Deficits in a Mouse Model of Alzheimer Disease

Recent advances in tau-directed immunotherapy against Alzheimer’s disease: an overview of pre-clinical and clinical development

Self-Therapeutic Nanoparticle That Alters Tau Protein and Ameliorates Tauopathy Toward a Functional Nanomedicine to Tackle Alzheimer's.

A Multi-Targeting Immunotherapy Ameliorates Multiple Facets of Alzheimer’ S Disease in 3xtg Mice

DNA vaccines targeting amyloid-β oligomer ameliorate cognitive deficits of aged APP/PS1/tau triple-transgenic mouse models of Alzheimer’s disease

Advances in Immunotherapies and Drug Development Prospect for Alzheimer's Disease

Systemic Administration of Neurotransmitter-Derived Lipidoids-PROTACs-DNA Nanocomplex Promotes Tau Clearance and Cognitive Recovery for Alzheimer's Disease Therapy

Disease Modifying Monoclonal Antibodies and Symptomatic Pharmacological Treatment for Alzheimer's Disease

Tau in Alzheimer's Disease: Mechanisms and Therapeutic Strategies.

Virus-like particle (VLP)-based vaccine targeting tau phosphorylated at Ser396/Ser404 (PHF1) site outperforms phosphorylated S199/S202 (AT8) site in reducing tau pathology and restoring cognitive deficits in the rTg4510 mouse model of tauopathy

A multi-targeting immunotherapy ameliorates multiple facets of Alzheimer's disease in 3xTg mice